

2024 CANCER SURVIVORS HALL OF FAME DINNER 2024 Honorees



Humanitarian Honoree
Richard T. Silver, MD

In recognition of his generosity and compassion, the CR&T Board of Directors unanimously elected to recognize Dr. Silver with this year's Humanitarian Award. As uncomfortable as this accolade will make Dr. Silver feel, the CR&T Board of Directors also chose to recognize his legacy by renaming the Humanitarian Award after him and honoring him with the inaugural **Richard T. Silver, MD Humanitarian Award**.

Dr. Silver is Professor Emeritus of Medicine and Emeritus Director, Richard T Silver MD Myeloproliferative Neoplasms Center, at Weill Cornell Medicine. He received undergraduate and medical degrees from Cornell University and completed an internship and residency (hematology/oncology) at New York Hospital-Cornell Medical Center. He was a Clinical Associate at the National Cancer Institute, NIH. As a Visiting Fulbright Professor at the University of Bahia, Salvador, Brazil, Dr. Silver helped establish a residency program, supported by the Rockefeller Foundation. His research included the study of blood groups of indigenous tribes of the Mato Grosso region of the Amazon, which led to his discovery of a rare blood subgroup.

Dr. Silver is an internationally recognized pioneer in clinical cancer chemotherapy and clinical and translational investigations in the myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia. He is particularly known for the broad clinical application of the interferons for treating these diseases and is widely credited with developing and popularizing the use of the bone marrow biopsy technique used worldwide for diagnosing hematologic disorders.

He is a prolific author and lecturer at many national and international meetings and has held many distinguished visiting professorships. He has co-chaired 15 international congresses on MPNs. He has been awarded a number of prestigious awards and honors from institutions worldwide. The Richard T Silver Distinguished Professor of Hematology and Oncology and the Richard T Silver MPN Center at Weill Cornell Medicine have been named in recognition of his contributions to the understanding of cancers and the MPNs.

continued on page 2



(Above) Dr. Silver, (middle top) Dr. Silver Recognized for Excellence in Hematology WCM, 2020, (lower middle left) Int'l Sci. Seminar 1990, (lower middle right) Rüdiger Hehlmann, MD presents Dr. Silver with the 2019 ELN Merit Award, (right) Dr. Silver and Jerry Lewis.



Cancer Survivor Honoree
Ruth Fein Revell

Ruth Fein Revell is a health/science writer, patient advocate, and author of the forthcoming book *The Big C² - stories from the chronic side of cancer*. She has lived with an MPN (myeloproliferative neoplasm) for more than 25 years. Her journalism training always her guide, she is known for translating medical specialist and researcher interviews into compelling, understandable features and blogs. Her stories have been published in numerous magazines, newspapers, trade journals and websites since she first freelanced while raising two boys in Upstate New York. She is a former regular contributor to *The New York Times* and currently writes for health and environmental websites, including most recently for *Well*, a New York Times newsletter. She regularly appears as a patient advocate on webinars. She is the author of *A crazy year - it isn't easy!* - a children's book told by a 9-year-old living through the 2020 pandemic, with hope and a few chuckles along the way. Coming out in late Fall 2024, *The Big C² - stories from the chronic side of cancer* - will dive into how survivors can become thrivers, despite the challenges of a chronic cancer. More about Ruth's story can be found in CR&T news Summer 2024 (www.crt.org/latest-news).



Ruth Fein Revell being interviewed by John Mascarenhas, MD



So Much More Than a Dinner

Honoring a Life: Moving On and Moving Forward



AJ Shiekman,
CR&T Board
Member & Young
Professional
Co-Leader

My father passed away in January of 2016 from stage 4 metastatic lung cancer. During my father's fight with cancer, I felt I had a purpose: to support him through his treatment (chemo, surgeries, radiation, and recovery). The two years while he was undergoing treatment felt like I was working two jobs: one during the day at an office and the second at the hospital at night with my father.

The evening after he passed away, I locked myself in a room and wrote his obituary. I wanted to honor him, his life, and his fight with cancer. The final line of my father's obituary read, "In lieu of flowers, the family requests that donations be made to the Cancer Research & Treatment Fund (CRT.org)." CR&T continues to give me a way to honor

my father's memory by providing funding and support to the doctors and researchers working to find a cure. I joined the CR&T's Young Professionals group and was honored to accept Dr. Silver and Tom Silver's invitation to join the Board of Directors, and I view it as a lifelong commitment.

Cancer Research & Treatment Fund's Cancer Survivors Hall of Fame Dinner isn't just another date on the calendar. The Hall of Fame Dinner sticks with you because it's about real people, real battles, and real struggles against cancer. It's about the grit, love, and spirit shown by everyone affected by the disease. We gather not just to clap for survivors but to remember and honor those who didn't make it. It's a night of true emotion and connection. And for me, it has a particularly special meaning.

I attended my first Cancer Survivors Hall of Fame Dinner

continued on next page



AJ Shiekman, center, with his Young Professionals dinner guests at 2022 Cancer Survivors Hall of Fame Dinner

shortly after my father passed away. The Cancer Survivors Hall of Fame Dinner represents the culmination of a year's research and progress achieved in the lab and by patients undergoing personal battles with cancer. Having witnessed the incredible strides made by CR&T over the years and the tangible impact on patients' lives, the dinner serves as a reminder of why we persist in this fight against cancer.

Each dinner takes on some of the characteristics and personality of the honorees. Previous cancer survivor honorees include Peter Criss (co-founder and original drummer from KISS), Harry Belafonte, John McCain, Michael Milken, and Fran Drescher ("The Nanny"). Among the distinguished physicians who have been honored are Dr. Malcolm Moore, the biologist who discovered the granulocyte growth factor filgrastim, Dr. Alexander Swistel, a distinguished surgeon at the Weill Cornell Breast Center, Dr. Anne Moore, an internationally respected expert in the field of breast cancer and Director of the Breast Cancer Survivorship program at Weill Cornell Medicine, and Dr. John Leonard, an expert in hematology and oncology and the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell. This year we honor Ruth Fein Revell as our Cancer Survivor. She has helped so many as a patient advocate and by sharing her story through her writings. It's also an exciting year as we honor CR&T founder Dr. Richard T. Silver, with the inaugural Richard T. Silver, MD Humanitarian Award. Knowing how many people he has helped over the years is truly inspiring and reminds me why I joined CR&T.

Everyone is welcome to attend the Dinner! If you've been touched by cancer, want to support the cause, or simply wish to learn more. Attending the Dinner provides an opportunity to contribute to CR&T's mission across two key areas:

1. Support a community of people that are impacted by cancer (family, friends, and loved ones), share stories, and learn from others.
2. Provide resources to physician researchers in their work to find new treatments and ultimately a cure for this disease which has impacted so many.

I'd like to personally invite you to come to this year's CR&T Cancer Survivors Hall of Fame Dinner. When you come, you'll join a group of people unified by a common cause. You'll hear powerful stories from those who've faced cancer and learn about new research being driven through CR&T Silver MPN Center, Weill Cornell, the medical advisory board. You can connect with others, hear inspiring stories and leave proud you contributed to such a worthy organization.

AJ Shiekman is a Director of Product Management for Pure Storage, a global data storage infrastructure company. He lives on the Upper West Side with his wife. In his downtime he enjoys golf, skiing and travel.

Since 1968, CR&T is proud to have maintained our mission to fund research emphasizing the cause, prevention, treatment, and cure of myeloproliferative neoplasms (MPNs) and also fund other blood and solid tumor cancer research. While we continue our emphasis on MPNS, in 2024, we have increased our funding for solid tumor cancer research to demonstrate our dedication to tackling a wider range of cancer types. This year, a major initiative includes a grant awarded to **Despina Siolas, MD, PhD** from Weill Cornell Medicine which will fund her project on “Investigating the immunogenicity of mutant Kras in pancreatic cancer”, with a goal of understanding how a tumor’s DNA makeup can profoundly shape the number and types of immune cells surrounding the tumor.

Project Summary

Project Title: Investigating the immunogenicity of mutant Kras in pancreatic cancer

Focus Area Addressed by Project: Pancreatic cancer, causes and treatment of solid tumor cancers

Lay Project Abstract:

Pancreatic cancer is a deadly disease with few treatment options. Immunotherapy is an exciting new cancer therapy, but it has limited efficacy in pancreatic ductal adenocarcinoma (PDA). Understanding why PDA tumors are resistant to immunotherapy will increase sensitivity to current treatments, improving patient outcomes.

Tumors are not simply cancer cells, but consist of other cell types, including immune cells. A tumor’s DNA makeup can profoundly influence the number and types of immune cells surrounding the tumor, but the specific mutations directing immune response and their associated biochemical mechanisms are poorly understood. KRAS gene mutations are present in almost all pancreatic tumors, though there is considerable variation in patient outcomes depending on KRAS genotype. Patients with KRASG12D mutations (representing 40% of PDA cases) have poorer prognoses compared to those with KRASG12R mutations (comprising 20% of PDA cases) suggesting that KRAS mutation status affects disease behavior. Our poor understanding of the different Kras mutations limits our ability to design and implement appropriate treatments. The goal of this proposal is to identify immune cells within KrasG12R PDA tumors and decipher its underlying biochemical mechanism. Our preliminary data from patient samples and mouse models reveal KRASG12R mutant tumors have a distinct immune cell population consisting of CD4+ T cells and activated dendritic cells in comparison to KRASG12D mutant tumors. The presence of dendritic cells, CD4+ T cells, and KRASG12R genotype are each linked independently to prolonged survival in PDA patients, the specific immune effects directly attributable to the KRASG12R mutation in PDA remain undefined. We will define the role of specific types of dendritic cell and CD4+ T cells and their cytokine mediators in driving KRASG12R tumor growth using both mouse models and human tumor samples. In addition, we will identify biochemical signaling differences between KRASG12R and KRASG12D mutant tumors that affect tumor immunity. Ultimately, we aim to develop tailored and effective therapeutic strategies for patients with PDA.

Dr. Despina Siolas received her Bachelor of Science with summa cum laude honors from St. John’s University. She attended medical school at Stony Brook University, where she was awarded the prestigious E-Trade Financial Scholarship from the Hellenic Medical Society of New York. In addition to



her MD degree, Dr. Siolas is the recipient of a Doctor of Philosophy in Genetics from the State University of New York at Stony Brook for studies she conducted in the lab of Greg Hannon PhD, Howard Hughes Medical Institute Professor, at Cold Spring Harbor Laboratory. She completed her internal medicine residency training and hematology/oncology fellowship at NYU Langone Health. Dr. Despina Siolas’ decision to pursue a career in medicine was deeply influenced by her mother’s cancer diagnosis. She became a medical oncologist to care for people with cancer, support them and their family members, and also work on new cancer therapies through her research. She specializes in treating people who have gastrointestinal (GI) cancers, including cancer of the colon, stomach, liver, pancreas, gallbladder, and esophagus. As a physician-scientist, her career goal is to pursue research questions with high translational potential for curing patients with gastrointestinal cancers.

In addition to treating patients, Dr. Siolas conducts research on cancer genes that influence the immune microenvironment using preclinical models of pancreatic cancer and colon cancer. Her research resides at the intersection of cancer genetics and tumor immunology with the goal of understanding how tumor genotype can affect the immune microenvironment and ultimately guide immunotherapy selection for patients. She has authored numerous publications, including a recently published manuscript in Cell Reports, and has been selected for oral presentation at three national meetings. She has received a prestigious Mentored Clinical Scientist Research Career Development Award (K08) from the National Institute of Health. She is a member of the American Society for Clinical Oncology, the American Association for Cancer Research, and American Medical Association, and Hellenic Medical Society and regularly presents her research at the AACR Annual Meeting. Dr. Siolas has secured a tenure track position and established a laboratory at Weill Cornell Medicine. (<https://siolaslab.weill.cornell.edu>).

You can listen to Dr. Siolas speak about Diagnosing and Treating Pancreatic Cancer with Dr. Leonard on his podcast, CancerCast wherever you listen to podcasts or at <https://bit.ly/3yu94rg>

Follow CR&T’s social media to keep up to date on this and other CR&T-fund cancer research. <https://www.crt.org/sign-up>

A Routine Exam Leads to a Path of Discovery and Resilience

In February of 2022, after a routine annual medical exam, I was diagnosed with polycythemia vera (PV). Last year, as I was exploring the Cancer Research and Treatment Fund (CR&T) website, I learned about the 12th International Patient Symposium on Myeloproliferative Neoplasms (MPNs). This was just what I was seeking - a day of hearing leading MPN doctors speak on the newest treatments and research.

I had so many questions about nutrition, how PV affects the heart, and how different doctors thought about and approached treatment protocol with patients. I was excited to attend a symposium geared to help patients better understand the science and research going on in different countries and hear the doctors in dialogue with one another.

The months leading up to the Symposium ushered in a seismic shift in how I experienced myself. My disease was invisible; I felt tired. In just one year, since diagnosis, I'd gone from having episodes of blurred vision and elevated hematocrit and hemoglobin levels to becoming anemic. The journey began when my internist set up a meeting with a Hematologist who confirmed my diagnosis of PV. After three phlebotomies, where the hematocrit levels were still dangerously high, the hematologist set up time on the apheresis machine which reduced my hematocrit levels by 20 points in 30 minutes. While he saved my life, he wouldn't consider the new drug targeted for my condition, as his team didn't recommend it for patients.

What I needed was a conference for patients with MPNs, where all the latest research and treatment approaches were discussed with patients, where our questions were answered.

CR&T's MPN Symposium was uplifting and empowering. It provided evidence of the changed ways I saw my world regarding diet and how I lived my life. Listening to the presentations, I felt that I was immersed in a giant detective story assimilating different ways of knowing. Everything they explained was understandable. In the afternoon, we broke into "disease specific" small groups. MPN patients who attended the Symposium were from all over the United States and the world. While I had always felt like a strong self-advocate, I gained more confidence to ask questions that needed further

exploration. It was important to attend this Symposium in person, because I met other MPN patients, doctors, and related health professionals. I felt I belonged to a supportive group who immediately got the complicated picture. Since the MPN Symposium, I have also joined CR&T's patient committee so that I can provide additional input on new topics for the symposium and become linked in with the MPN universe of research.



CR&T's MPN Symposium was uplifting and empowering. It provided evidence of the changed ways I saw my world regarding diet and how I lived my life... I felt I belonged to a supportive group who immediately got the complicated picture.

This year, CR&T's 13th International Patient Symposium on Myeloproliferative Neoplasms (MPNs) is Wednesday, October 23, 2024, and the program looks great. The presentations will address some of my primary concerns 1) Cardiovascular Health in MPN patients (Stephanie Feldman, MD), and Origins and Genetics of MPNs (Linda Resar, MD). It's a great opportunity to bring along friends and family members, so they are informed about what you are going through.

Shoshanah [last name omitted] was diagnosed with PV in 2022 and is an active member of CR&T's Patient Committee. She lives in CT with her supportive family and pets.



13TH INTERNATIONAL PATIENT SYMPOSIUM ON MYELOPROLIFERATIVE NEOPLASMS

Wednesday, October 23, 2024

Belfer Research Building · Weill Cornell Medicine
413 East 69th Street · New York, NY 10021

REGISTRATION FORM

Registration is \$175 for patients or for
the first registrant; \$100 for your guest.

Register and/or donate online at

www.crt.org/patient-symposium-on-mpns

or complete this form, which may be mailed to CR&T, 500
E. 77th Street, Ste. 1001, New York, NY 10162; emailed to
cfeay@crt.org; or faxed to 212-288-7704.

If the fee is a financial hardship for you, please contact
cfeay@crt.org for scholarship information.



Registration (Please print)

*Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____

*Email: _____

Guest: _____

Guest: _____

Guest: _____

*Select Breakout Group:

☐ Polycythemia Vera ☐ Myelofibrosis

☐ Essential Thrombocythemia

Sponsorships/Donations:

☐ Benefactor (\$10,000) ☐ Founder (\$5,000)

☐ Contributor (\$2,500) ☐ Friend (\$1,000)

☐ Supporter (\$500) ☐ Donor (\$100)

Payment: Please make check payable to:
Cancer Research & Treatment Fund

Payment: ☐ Check ☐ MasterCard ☐ Discover

☐ Visa ☐ American Express

Credit Card #: _____

Total Amount Charged: _____

Card Verification #: _____ Exp. Date: _____

Name as it appears on card: _____

credit card numbers, once processed, are not retained

Signature: _____

*Required

PROGRAM

8:00 AM Registration/Continental Breakfast

8:45 AM **Welcome and Introduction**
Ghaith Abu-Zeinah, MD - Symposium Chair,
Weill Cornell Medicine
Jedd Wolchok, MD, PhD, FASCO - Meyer
Director of the Sandra and Edward Meyer
Cancer Center at Weill Cornell Medicine
David T. Boule, Patient Committee Chair, CR&T

9:00 AM **Origins and Genetics of MPNs**
Linda Resar, MD

9:30 AM **Inflammation in the MPNs**
Hans Hasselbalch, MD, PhD

10:00 AM **Cardiovascular Health in MPN Patients**
Stephanie Feldman, MD

10:30 AM **Break/Exhibits**

11:00 AM **Symptom Relief, Diet, and Exercise in
MPN Patients**
Ruben Mesa, MD

11:30 AM **MPN Progression: Is it predictable?**
Ghaith Abu-Zeinah, MD

12:00 PM **Accelerated and Blast-Phase MPNs**
Raajit Rampal, MD, PhD

12:30 PM **Lunch/Exhibits**

1:30 PM **Drugs-Novel Agents for MPNs in 2024**
Naveen Pemmaraju, MD

2:00 PM **Moderated Q&A**
Ghaith Abu-Zeinah, MD, and Entire Panel

3:00 PM **Break/Exhibits**

3:30 PM **Disease-Specific Sessions and Q&A Groups**
Polycythemia Vera
Managing PV in 2024 - Richard T. Silver, MD
Q&A - Drs. Abu-Zeinah, Hasselbach, Silver

Essential Thrombocythemia
Managing ET in 2024 - Ellen Ritchie, MD
Q&A - Drs. Ritchie, Schafer, Mesa, Resar

Myelofibrosis
Managing MF in 2024 - Ronald Hoffman, MD
Q&A - Drs. Hoffman, Pemmaraju, Rampal

5:00 PM **Wine & Cheese Reception**

6:00 PM **Adjournment**

Speakers and Schedule Subject to Change



Dear Supporters and Friends,

Our mission to fund research emphasizing the cause, prevention, treatment, and cure of myeloproliferative neoplasms (MPNs) and also other blood and solid tumor cancer research remains steadfast, and, with your ongoing support, we are excited about the progress being made in both our traditional areas of focus and new frontiers.

This year, we have continued our dedicated support for physician-scientists and their groundbreaking research into the understanding and treatment of cancer. Our ongoing commitment to myeloproliferative neoplasms (MPNs) remains strong. Additionally, we have increased our funding for solid tumor cancer research, reflecting our commitment to addressing a broader spectrum of cancer types.

This year, one of our key initiatives is a grant awarded to Despina Siolas, MD, PhD from Weill Cornell Medicine. In addition to treating patients, Dr. Siolas conducts research on cancer genes that influence the immune microenvironment using preclinical models of pancreatic cancer and colon cancer. With the funding provided by CR&T, Dr. Siolas' research goal is to understand how a tumor's DNA makeup can profoundly shape the number and types of immune cells surrounding the tumor. Understanding why pancreatic tumors are resistant to immunotherapy will help improve sensitivity to current treatments and improve patient outcomes (page 4).

Officially dedicated in 2014, CR&T's support for the Richard T. Silver, MD Myeloproliferative Neoplasms (MPN) Center continues to be a cornerstone of our efforts. With CR&T contributing nearly \$8 million to date, this center of excellence boasts one of the most comprehensive MPN patient databases and biospecimen collections in the country. Using this database, along with machine learning, is vital for advancing MPN research as it significantly advances medical research and patient care, as well as, enables the analysis of vast amounts of medical data rapidly and effectively, enabling researchers to analyze genetic, molecular, and clinical data, leading to a better understanding of MPNs.

We are also proud to highlight the continued success of CR&T-Associated researchers, whose work has been prominently featured in esteemed journals and events. Noteworthy publications include Abu-Zeinah et al. in *Annals of Hematology*, Chamseddine et al. in *Blood Advances*, Abu-Zeinah et al. in the *Blood Cancer Journal*, Silver et al. in *Leukemia*, and Silver et al. in *Expert Review of Hematology*. Additionally, CR&T-Associated researchers have several articles in review with more forthcoming. This year, over thirteen abstracts were submitted for the Annual Meeting of the American Society of Hematology (ASH) covering topics such as MPN treatments and data-based outcomes, AI and image analysis, and trials in progress. Read more online: <https://www.crt.org/research-updates> (page 11).

The election cycle of our Board of Directors has reinforced the stability and quality of our governance. I am pleased to announce that all members of the Class of 2024 have agreed to extend their terms for another 3 years, ensuring continuity and expertise in our leadership. We continue our multigenerational membership as Rajesh Shah joined the Board. As the son of long-standing Board Member Bharat Shah, Rajesh brings a historic knowledge while adding his own passion to ensure that CR&T's mission continues to be fulfilled. We are grateful for the many contributions and years of service of two of our board members: Bharat Shah, who stepped down, and Joe Aimi, who passed away earlier this year. We extend our heartfelt condolences to the Aimi family (page 10).

None of these achievements would be possible without the generous support of our donors. Your contributions, through donations and events like the MPN Patient Symposium and the Cancer Survivors Hall of Fame Dinner, play a crucial role in our mission.

Thank you for your continued support and commitment to our cause. Together, we are making significant strides in the fight against cancer.

Warm regards,

A handwritten signature in black ink that reads "Tom".

Tom Silver
President, Board of Directors
Cancer Research & Treatment Fund



2024 CANCER SURVIVORS HALL OF FAME DINNER

Thursday, November 21, 2024

HUMANITARIAN AWARD

RICHARD T. SILVER, MD
Professor Emeritus of
Medicine, Emeritus
Director, Silver MPN
Center, Weill Cornell
Medicine, NY, Vice
President & Medical
Director, Cancer Research
& Treatment Fund

CANCER SURVIVOR HONOREE

RUTH FEIN REVELL
Health/Science Writer,
Rare Cancer Patient
Advocate



Please register online at
[www.crt.org/
Hall-of-Fame-Event](http://www.crt.org/Hall-of-Fame-Event)
or use this card.

TABLES (please indicate quantity below)

- **\$25,000 HALL OF FAME PACKAGE**
Reception and Premium Table for 10 guests. Two-page spread in the Dinner journal. Signage and special listing in all printed material. Special acknowledgment in the CR&T newsletter and on website.
- **\$15,000 BENEFACTOR PACKAGE**
Reception and Special Table for 10 guests. Gold page advertisement in the Dinner journal. Listing as Benefactor in all printed material. Special acknowledgment in CR&T newsletter.
- **\$11,000 FOUNDER PACKAGE**
Reception and Table for 10 guests. Silver page advertisement in the Dinner journal. Listing as Founder in all printed material. Special acknowledgment in CR&T newsletter.
- **\$8,000 CONTRIBUTOR PACKAGE**
Reception and Table for 10 guests. Special acknowledgment in CR&T newsletter.

INDIVIDUAL TICKETS (please indicate quantity below)

All tickets include Reception and Dinner

- \$1,100 Founder Ticket(s)
- \$800 Contributor Ticket(s)

JOURNAL ADS (please indicate quantity below)

- \$3,000 Gold Page
- \$1,100 Silver Page

CONTRIBUTIONS

- ☐ I cannot attend, but wish to make a tax-deductible donation of \$_____ to Cancer Research & Treatment Fund, Inc.

If purchasing a journal ad, either individually or as part of a package, please be sure to enter text in the comment box on checkout.



Past HOF Dinners



Name _____
(Please print exactly as you wish to be listed)

☐ Check here if you do not wish to be acknowledged in CR&T's printed materials and on website

Title _____

Firm _____

Address _____

City _____

State _____ Zip _____

Phone _____

Email _____

Please choose one:

☐ Check enclosed \$ _____

☐ Please charge my credit card \$ _____

☐ Check here to cover credit card transaction fees.

☐ MasterCard ☐ Visa ☐ American Express

Card Number _____ Expiration Date _____

Signature _____ Security Code _____

Credit card name/billing address if different from above:

Please make checks payable to:

Cancer Research & Treatment Fund, Inc.

Mail to: Cancer Research & Treatment Fund, Inc. • Attention: Chad Feay
500 East 77th Street, Suite 1001 • New York, NY 10162

If purchasing a table, please include a list of your guests.

For further information, please contact: Chad Feay, 212.288.6604 /
Email: events@crt.org

Lymphoma, Leukemia & Myeloma Congress

October 16-19, 2024 • New York City, NY

www.hmpglobalevents.com/llmcongress



WEDNESDAY
OCTOBER 23, 2024

13TH INTERNATIONAL PATIENT SYMPOSIUM ON MYELOPROLIFERATIVE NEOPLASMS

Hosted by Cancer Research & Treatment Fund



Learn More!

www.crt.org

Thank you to our sponsors



16th International Congress
Myeloproliferative Neoplasms
October 24-25, 2024 • Brooklyn, New York

Patients and caregivers are invited to attend this 2-day professional education conference to learn about the latest scientific, clinical and therapeutic developments in myeloproliferative neoplasms.



Scan and register today!



Richard T Silver, MD
Weill Cornell Medicine
Chairman, MPN Congress

Jerry L Spivak, MD
Johns Hopkins University School of Medicine
Co-Chairman, MPN Congress

Meeting Organizer

MME

Melton Medical Education, LLC

Email: info@MeltonMedEd.com

www.MPNcongress2024.com



2024 CANCER SURVIVORS HALL OF FAME DINNER

Thursday November 21, 2024

THE ESSEX HOUSE • 160 Central Park South • New York, NY

<https://www.crt.org/hall-of-fame-event>



Scan For More Info



CR&T welcomes new Board Member Rajesh (Raj) Shah, Chief Investment Officer - The Hardy Group. Raj joined The Hardy Group in 2022 with over 25 years of experience as a private investor and operator of commercial real estate; including hospitality, senior housing, retail, office, and light industrial assets. Raj's background as an entrepreneurial, detail-oriented, real estate professional was the basis for his role as the company's first Chief Investment Officer. Prior to joining The Hardy Group, Raj served as Principal/Managing Director at The Diwan Group, Pinnacle Real Estate Partner, and a Principal at Noble Investment Group.

Raj earned his Bachelor of Science in Business Administration (BSBA) from the University of North Carolina Chapel Hill, Chapel Hill, North Carolina and his Masters of Management in Hospitality (MMH) with a concentration in Real Estate and Finance from Cornell University, Ithaca, New York. Mr. Shah holds his North American Securities Administrators Association (NASAA) Series 7, Series 63 and the Series 66 securities licenses (inactive).

Raj brings with him a personal connection to Dr. Silver and the CR&T family through his father, Dr. Bharat Shah, a long-standing board member. We are grateful to have the Shahs join other multi-generational Board Member families. In 2000, Dr. Shah was diagnosed with CML and through God's grace and good fortune, was introduced to Dr. Silver and accepted into the clinic trials for STI571. For twenty-four years, the Shah family has been under the care and guidance of Dr. Silver, and Dr. Shah has continued to thrive in his daily life. Raj lives in Atlanta, GA with his long-term girlfriend, Bonnie Herring, and their three fantastic dogs. Welcome Raj.



CR&T congratulates Medical Advisory Board Member Ghaith Abu-Zeinah, MD as a recipient of the American Society of Hematology (ASH) Scholar Award. ASH's most prestigious research award program, the ASH Scholar Award supports early career investigators dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. The program funds hematologists in the United States and Canada who conduct basic, translational, and clinical research that advances the understanding and treatment of blood disorders. The Scholar Award will provide Junior Faculty level funds of \$150,000 for clinical research toward myeloproliferative neoplasms research utilizing artificial intelligence and machine learning. Full press release: <https://bit.ly/CRTMAB>

CR&T Board Elections

CR&T is proud to announce the reelection of our Directors in September 2024 (each year CR&T elects a portion of its Board members to a three-year term). All of these members willingly stood for reelection, and they were unanimously elected to continue their service on the Board for another three-year term. This resounding vote of confidence underscores the quality and stability of our Board, reinforcing our unique ability to fulfill CR&T's mission effectively.

Additionally, we welcome second-generation board member, Rajesh Shah, who was unanimously elected to serve on CR&T's Board of Directors. We are pleased he has decided to continue the support of the CR&T mission well established by his father Bharat Shah and the Shah family. We are grateful to Bharat Shah, PhD for so many years of support and service on CR&T's Board of Directors. Bharat steps down after a storied history of involvement from speaking to Dr. Silver's first year medical students over the years, to receiving CR&T's Humanitarian Award at the Cancer Survivors Hall of Fame Dinner in 2017. While he may be stepping down from the board at this time, we are grateful for his ongoing support and are assured that the legacy he created will continue well into the future.

Class of 2024

- Terry Hermanson, *President, Mr. Christmas Inc.*
- Michael C. Kempner, *Managing General Partner, KS Capital Partners, L.P.*
- Kasia McCormick
- Amanda Johns Perez
- Richard J. Rose, *Senior Managing Partner, Retired, Shufro, Rose & Co., LLC*
- Rajesh Shah *Chief Investment Officer, The Hardy Group*
- AJ Shiekman, *Strategy/Business Development Manager, Pure Storage*
- Thomas M. Silver, *Principal, Silver Dollar Ventures, LLC*
- Tim Silver, *Portfolio Manager, Empery Asset, LP*
- Anne Templeton

Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih WJ, Zagrijtschuk O, Sato T, Shimoda K, **Silver RT**, Mesa R. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis. *Ann Hematol*. 2024 Sep;103(9):3573-3583. doi: 10.1007/s00277-024-05912-8. Epub 2024 Aug 15. PMID: 39145781; PMCID: PMC11358163.

Grunwald MR, **Ritchie EK**, Rumi E, Assad A, Hamer-Maansson JE, Yu J, Kalafut T, Braunstein E, Passamonti F. Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched-cohort analysis. *eJHaem*. 2024 Jul 19;5(4):778-783. doi: 10.1002/jha2.954. PMID: 39157625; PMCID: PMC11327719.

Abu-Zeinah G, **Erdos K**, **Lee N**, Lebbe A, Bouhali I, Khalid M, **Silver RT**, **Scandura JM**. Are thrombosis, progression, and survival in ET predictable? *Blood Cancer J*. 2024 Jun 5;14(1):103. doi: 10.1038/s41408-024-01079-7. PMID: 38918372; PMCID: PMC11199579.

Chamseddine RS, Savenkov O, Rana S, Khalid M, **Silver RT**, Kucine N, **Scandura JM**, **Abu-Zeinah G**. Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety

and outcomes. *Blood Adv*. 2024 May 28;8(10):2520-2526. doi: 10.1182/bloodadvances.2023012459. PMID: 38507746; PMCID: PMC11131058.

Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, Sotelo J, Potenski C, Mimitou EP, Stahl M, El Ghaity-Beckley S, Arandela J, Raviram R, Choi DC, Hoffman R, Chaligné R, Abdel-Wahab O, Smibert P, Ghobrial IM, **Scandura JM**, Marcellino B, Levine RL, Landau DA. Mapping genotypes to chromatin accessibility profiles in single cells. *Nature*. 2024 May;629(8014):1149-1157. doi: 10.1038/s41586-024-07388-y. Epub 2024 May 8. PMID: 38720070; PMCID: PMC11139586.

Kremyanskaya M, Kuykendall AT, Pemmaraju N, **Ritchie EK**, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R; REVIVE Trial Investigators. Rusfertide, a Hcpidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. *N Engl J Med*. 2024 Feb 22;390(8):723-735. doi: 10.1056/NEJMoa2308809. PMID: 38381675.

CR&T-Associated Researchers indicated in **bold**.



Cancer Research & Treatment Fund, Inc. (CR&T)

500 E. 77th Street, Suite 1001
New York, NY 10162
Phone: 212-288-6604
Email: info@crt.org
www.crt.org

ABOUT CR&T

Since 1968, CR&T has funded the world's most promising physician-scientists, equipping them with the resources to advance the treatment of various types of blood cancers, including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma, as well as other common cancers, such as breast and lung cancer.

STAFF

Chad Feay, MA, CHES
Director of Administration and Development
Mara Sanderson
Administrative Specialist

CR&T NEWS

Writer: Chad Feay, MA CHES
Designer: Zenaïda Mendoza
Printer: WW Printing Corp

Board of Directors

Thomas M. Silver, President
Principal, Silver Dollar Ventures, LLC

Richard T. Silver, MD, Vice President, Medical Director
Weill Cornell Medicine

David T. Boule, Treasurer
Retired Partner, Ernst & Young

Nelson A. Boxer, Counsel
Partner, Petrillo Klein & Boxer LLP

Maria Brisbane, CFA
Managing Director, Morgan Stanley

Terry Hermanson
President, Mr. Christmas, Inc.

Michael C. Kempner
Managing General Partner, KS Capital Partners, L.P.

Kasia McCormick

Amanda Johns Perez

Jeffrey Puglisi, MD
Glenville Medical Concierge Care

Richard J. Rose
Senior Managing Director (retired),
Shufro, Rose & Co., LLC

Rajesh Shah, PhD
Chief Investment Officer - The Hardy Group

Todd J. Shaw
First Vice President, Morgan Stanley

AJ Shiekman
Strategy/Business Development Manager, Pure Storage

Adam Silver

Tim Silver
Portfolio Manager, Empery Asset Management, LP

Anne Templeton

Medical Advisory Board

Richard T. Silver, MD
Vice President & Medical Director
Weill Cornell Medicine, New York, NY

Morton Coleman, MD
Associate Scientific Director
New-York Presbyterian Hospital/Weill Cornell Medicine,
New York, NY

Mark W. Pasmantier, MD
Associate Medical Director
New-York Presbyterian Hospital/Weill Cornell Medicine,
New York, NY

Ghaith Abu Zeinah, MD
New-York Presbyterian Hospital/Weill Cornell Medicine,
New York, NY

Edward P. Ambinder, MD
Icahn School of Medicine at Mount Sinai, New York, NY

John P. Leonard, MD
New-York Presbyterian Hospital/Weill Cornell Center for
Lymphoma and Multiple Myeloma, New York, NY

Anne Moore, MD
Weill Cornell Breast Center, New York, NY

Malcolm Moore, DPhil
Memorial Sloan Kettering Cancer Center, New York, NY

Shahin Rafii, MD
Weill Cornell Medicine, New York, NY

Joseph M. Scandura, MD, PhD
Weill Cornell Medicine, New York, NY

Andrew I. Schafer, MD
Weill Cornell Medicine, New York, NY

David A. Scheinberg, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

Jerry L. Spivak, MD
Johns Hopkins Medicine, Baltimore, MD

Alexander J. Swistel, MD
New-York Presbyterian Hospital/Weill Cornell Breast Center,
New York, NY

CR&T News at your fingertips!

See the latest news, download an issue to your tablet or digital device, and browse archived issues!



CR&T Newsletters are published 3 times a year. Stay up to date on the latest CR&T developments in cancer research and treatments! Sign up for emails at www.crt.org/sign-up and follow us on social media!



(Facebook) @cancerresearchandtreatment



(X-formerly Twitter) @CRTFund



(LinkedIn) cancer-research-&-treatment-fund-inc



(YouTube) @cancerresearchtreatmentfund



www.instagram.com/cancerresearchtreatmentfund



Cancer Research & Treatment Fund, Inc.
Established 1968

Cancer Research & Treatment Fund
500 East 77th Street, Suite 1001
New York, NY 10162-0015



Cancer Research & Treatment Fund, Inc.
Established 1968

Fall 2024

Funding Cancer Research: Innovative. Agile. Experienced.



In this issue:

- Hall of Fame Dinner Honorees
- A Time to Honor and Move Forward
- Expanding CR&T's Impact
- From Routine to Resilience
- Patient Symposium Registration & Agenda
- Letter from CR&T President
- Hall of Fame Dinner Information
- Upcoming Events
- MAB & Board News
- Researcher Publications